注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Avalo Therapeutics Inc是一家临床级精密医疗公司。该公司为免疫学和罕见遗传病方面临床需求未得到满足的患者发现、开发和商业化治疗药物。其临床阶段项目包括AVTX-002、AVTX-007和AVTX-800项目。AVTX-002是一种抗轻型单克隆抗体,用于治疗非嗜酸粒细胞性哮喘、中重度炎症性肠病和2019冠状病毒疾病急性呼吸窘迫综合征。AVTX-007是一种全人类单克隆抗体,用于治疗斯蒂尔病,包括成人斯蒂尔病(AOSD)和系统性青少年斯蒂尔病(SJIA)。其AVTX-800程序包括AVTX-801和AVTX-803、AVTX-802、AVTX-008和AVTX-006。VTX-801和AVTX-803是治疗先天性糖基化障碍(CDGs)的单糖疗法。AVTX-006是一种双mTORc1/c2小分子抑制剂,用于治疗复杂的淋巴管畸形。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Philip P. Gutry | 48 | 2015 | Independent Director |
Anne B. Young | - | - | Member of Scientific Advisory Board |
Ronald T. Borchardt | - | - | Member of Scientific Advisory Board |
Gunnar Magnus Severus Modee Persson | 62 | 2012 | Lead Independent Director |
Robert H. Lenox | - | - | Member of Scientific Advisory Board |
Dennis C. Liotta | 74 | - | Member of Scientific Advisory Board |
Sol J. Barer | 75 | 2020 | Special Advisor & Strategic Advisory Board |
Garry A. Neil | 68 | 2020 | Chairman of the Board, President & CEO |
Gilla Kaplan | 75 | 2020 | Independent Director |
June S. Almenoff | 65 | 2021 | Independent Director |
Mitchell Chan | 41 | 2021 | Independent Director |
Barbara S. Slusher | 58 | - | Founder and Member of Scientific Advisory Board |
Solomon H. Snyder | 84 | - | Founder and Chairman of Scientific Advisory Board |
Jonathan Goldman | - | 2024 | Independent Director |
Aaron Kantoff | 38 | 2024 | Independent Director |
Samantha Scollard Truex | 53 | 2024 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核